The dose-effect relationship of baclofen in alcohol dependence: A 1-year cohort study

Human Psychopharmacology
Baptiste PignonBenjamin Rolland

Abstract

Our aim is to study the relationship between dose of baclofen and effectiveness in alcohol dependence. Two hundred two patients with alcohol dependence, who received baclofen treatment for drinking reduction, were followed up for 1 year. For each patient-month of treatment, the maximum daily dose of baclofen (DDB) and average weekly alcohol consumption (AWAC) were calculated. We defined a favorable drinking outcome as an AWAC under 200 g/w for at least 2 consecutive months. We divided the DDB of each patient-month into 3 categories (low dose: <90 mg/d, medium dose: 90-150 mg/d, and high dose: >150 mg/d) and investigated the relationship between reaching a favorable outcome and the concurrent DDB category in a time-varying Cox regression analysis. Hazard ratios (HRs) were adjusted based on age, sex, and initial AWAC. One hundred forty subjects were followed during at least 1 month. Of these patients, 58 (41%) had a favorable drinking outcome. In comparison to low dose, medium dose was associated with a decreased rate of favorable drinking outcome (HR = 0.42; 95% CI [0.20, 0.88]), whereas no difference was found with high dose (HR = 1.31; 95% CI [0.65, 2.64]). The relationship between dose of baclofen and favorable drinking outco...Continue Reading

References

Jul 11, 1998·Alcoholism, Clinical and Experimental Research·A HillU John
Sep 10, 2002·Alcohol and Alcoholism : International Journal of the Medical Council on Alcoholism·Giovanni AddoloratoGiovanni Gasbarrini
Dec 15, 2004·Alcohol and Alcoholism : International Journal of the Medical Council on Alcoholism·Olivier Ameisen
Jul 29, 2010·Alcoholism, Clinical and Experimental Research·James C GarbuttBarbara A Flannery
Dec 24, 2010·Thérapie·Benjamin RollandOlivier Cottencin
Mar 19, 2011·Alcohol and Alcoholism : International Journal of the Medical Council on Alcoholism·Giovanni AddoloratoUNKNOWN Baclofen Study Group
Jul 12, 2011·Journal of Psychopharmacology·Jonathan Chick, David J Nutt
Feb 14, 2012·Addiction·Benjamin RollandOlivier Cottencin
Feb 21, 2013·Journal of Clinical Psychopharmacology·Benjamin RollandOlivier Cottencin
Apr 9, 2013·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Antoni GualUNKNOWN ESENSE 2 Study Group
Oct 22, 2013·Pharmacology, Biochemistry, and Behavior·Boris Tabakoff, Paula L Hoffman
Jun 7, 2015·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Christian A MüllerAndreas Heinz
Jun 20, 2015·Current Pharmaceutical Design·Antonio MirijelloGiovanni Addolorato
Jun 23, 2015·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Benjamin RollandOlivier Cottencin
Jul 25, 2015·Alcoholism, Clinical and Experimental Research·Bruce ImbertNicolas Simon
Nov 16, 2016·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Esther M BerahaReinout W Wiers

❮ Previous
Next ❯

Citations

Jul 1, 2017·Expert Opinion on Pharmacotherapy·Michael Soyka, Christian A Müller
Sep 8, 2018·Frontiers in Psychiatry·Nicolas SimonBenjamin Rolland
Sep 21, 2018·Frontiers in Psychiatry·Nicolas FranchittoNicolas Simon
May 21, 2019·Current Opinion in Psychiatry·Mehdi FarokhniaLorenzo Leggio
Jan 22, 2019·Frontiers in Psychiatry·Renaud de BeaurepaireRoberta Agabio
Sep 7, 2018·Frontiers in Psychiatry·Benjamin RollandNicolas Franchitto
Mar 27, 2018·Psychopharmacology·Erin J CampbellChristina J Perry

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.